{
    "clinical_study": {
        "@rank": "60649", 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine whether the anti-VEGF drug is effective at\n      stabilizing and/or improving vision in patients with the wet form of AMD"
        }, 
        "brief_title": "Phase II/III Study of Anti-VEGF in Neovascular AMD", 
        "completion_date": "July 2002", 
        "condition": [
            "Macular Degeneration", 
            "Choroidal Neovascularization"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Neovascularization, Pathologic", 
                "Choroidal Neovascularization"
            ]
        }, 
        "detailed_description": {
            "textblock": "This will be a randomized, double-masked, controlled, dose-ranging, multi-center comparative\n      trial, in parallel groups. Patients will be stratified by clinical center, by percentage of\n      classic CNV vessels: [predominantly classic (>50%) vs. minimally classic (1-49%) vs. purely\n      occult (0%)], and according to whether, or not, they have received prior PDT with Visudyne\n      (no more than once). All patients will be re-randomized after 54 weeks of treatment to\n      either, continue or discontinue therapy for further 48 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients of either gender, aged 50 years or above, diagnosed with subfoveal CNV secondary\n        to AMD and with best corrected visual acuity of 20/40 to 20/320 in the absence of\n        subfoveal atrophy or scarring in the study eye, and better or equal to 20/800 in the\n        fellow eye, may be enrolled. Clinically significant concomitant diseases will be excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": "540", 
        "firstreceived_date": "August 3, 2001", 
        "id_info": {
            "nct_id": "NCT00021736", 
            "org_study_id": "EOP1004B"
        }, 
        "intervention": {
            "intervention_name": "EYE001 anti-VEGF aptamer", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "keyword": [
            "choroidal neovascularization (CNV)", 
            "subretinal neovascularization"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland"
                }, 
                "name": "Foundation for Fighting Blindness"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II/III Randomized, Double-Masked, Trial, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative AMD).", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2/Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00021736"
        }, 
        "source": "Eyetech Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eyetech Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2002"
    }, 
    "geocoordinates": {
        "Foundation for Fighting Blindness": "39.29 -76.612"
    }
}